Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
Open Access
- 16 June 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (6), 575
- https://doi.org/10.3390/ph14060575
Abstract
The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using 68Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the regulatory framework for clinical trial application. The preparation of the radiopharmaceutical was established using a cassette-based automated synthesis unit. Product specifications, including analytical procedures and acceptance criteria, were adopted from Ph. Eur. monographs for other 68Ga-labeled radiopharmaceuticals. Non-clinical studies included receptor affinity and cell uptake studies using two different CCK2R-expressing cell lines, as well as pharmacokinetic biodistribution studies in BALB/c mice for dosimetry calculations and toxicological studies in Wistar rats. The produced masterbatches fulfilled the defined acceptance criteria. DOTA-MGS5, with confirmed affinity to the CCK2R, showed a high specific cell uptake and no interaction with other receptors in vitro when radiolabeled with gallium-68. Favorable in vivo properties were observed in biodistribution and dosimetry studies. An effective dose of ~0.01 mSv/MBq was estimated for humans utilizing OLINDA/EXM software. A maximum peptide dose of 50 µg was established for the initial clinical dose based on the toxicity study in rats. The standardized production of [68Ga]Ga-DOTA-MGS5 using an automated synthesis module and the performed non-clinical safety studies support a first exploratory clinical trial with this new PET imaging agent.Funding Information
- Austrian Science Fund (P 27844)
This publication has 38 references indexed in Scilit:
- Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2013
- Clinical applications of Gallium-68Applied Radiation and Isotopes, 2013
- Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumorsMolecular and Cellular Endocrinology, 2012
- Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Highly Improved Metabolic Stability and Pharmacokinetics of Indium-111-DOTA-Gastrin Conjugates for Targeting of the Gastrin ReceptorJournal of Medicinal Chemistry, 2011
- Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATEEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- A fully automated synthesis for the preparation of 68Ga-labelled peptidesNuclear Medicine Communications, 2007
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- Expression of chromogranin A and somatostatin receptors in pancreatic AR42J cellsMolecular and Cellular Endocrinology, 2002
- The Distribution of Active Bone Marrow in the AdultPhysics in Medicine & Biology, 1961